PURPLE BIOTECH LTD-ADR
PPBTNASDAQTrading Snapshot
- Day Range
- $0.91 – $0.96
- 52-Week Range
- $0.91 – $14.10
- Volume (shares)
- 10,387
- Avg Volume (shares)
- —
- Shares Outstanding
- 138,084
- Next Earnings
- 2026-11-13
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -0.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.26
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +480.5%
PURPLE BIOTECH LTD-ADR
PPBT
StockOtter · stockotter.spaceAbout PURPLE BIOTECH LTD-ADR
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies
REHOVOT, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the “Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to ma
Financial Review: Ionis Pharmaceuticals (NASDAQ:IONS) & Purple Biotech (NASDAQ:PPBT)
Ionis Pharmaceuticals (NASDAQ: IONS - Get Free Report) and Purple Biotech (NASDAQ: PPBT - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the s
Purple Biotech (PPBT) Expected to Announce Quarterly Earnings on Wednesday
Purple Biotech (NASDAQ: PPBT - Get Free Report) will likely be announcing its results before the market opens on Wednesday, August 5th. Analysts expect Purple Biotech to announce earnings of ($0.98) per share for the qua